• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Did Positive Phase 2 Results Just Shift AbCellera Biologics' (ABCL) Investment Narrative?

    Simply Wall St·10/26/2026 19:32:03
    Listen to the news
    • AbCellera Biologics reported positive top-line Phase 2 data for ABCL635 in postmenopausal vasomotor symptoms. A single 600 mg subcutaneous dose cut moderate to severe events by 8.8 per day at week four, compared with 3.5 for placebo in a 92 patient trial.
    • The ABCL635 readout gives AbCellera Biologics an internally owned asset with measurable symptom reduction in an area already crowded with small molecule competitors. This development could influence how investors view its shift from a pure discovery platform toward a clinical development model.
    • We will now assess how AbCellera Biologics' investment narrative could shift in light of ABCL635's single-dose Phase 2 efficacy signal.

    Scan beyond AbCellera Biologics and see how other antibody and biologics players with AI angles are lining up in our hand picked 34 healthcare AI stocks.

    AbCellera Biologics Investment Narrative Recap

    To own AbCellera Biologics, you need to believe the shift from pure antibody discovery to owning clinical assets can eventually support a bigger, more durable revenue base than partner fees alone. The short term focus sits on ABCL635 progressing cleanly through later studies, while the broader partnered portfolio keeps upfronts and milestones from fading too sharply.

    The biggest risk is still execution against high R&D spend and ongoing losses while facing entrenched vasomotor competitors. The recent ABCL635 Phase 2 data is important clinically but does not change that near term pressure on earnings and cash burn is very real if internal programs or partner pipelines stall or slip.

    Among recent AI related updates in the sector, MindWalk Holdings’ LensAI immunogenicity screening work is worth your attention as context. It shows how fast, large scale sequence analytics on cloud hardware can compress preclinical timelines for antibody design, which is directly relevant to what AbCellera Biologics and peers are trying to achieve on the discovery side.

    If tools like LensAI and NVIDIA’s BioNeMo Agent Toolkit gain wider adoption, investors may expect AbCellera Biologics to keep pace on AI driven workflows, not just wet lab capabilities. That cuts both ways. Efficient competitors could intensify pressure on AbCellera to convert platform science into differentiated, de risked clinical assets like ABCL635 and ABCL575 more consistently.

    AbCellera Biologics is modeled to reach forecast revenues of $41.7 million and earnings of $6.9 million by 2029. This implies revenues declining at 14.3% each year and an earnings swing of about $171.6 million from a loss of $164.7 million today to positive earnings of $6.9 million.

    Uncover why AbCellera Biologics' fair value indicates a 45% potential upside to its current price that could narrow quickly.

    NasdaqGS:ABCL 1-Year Stock Price Chart
    NasdaqGS:ABCL 1-Year Stock Price Chart

    Exploring Other Perspectives

    Where consensus sees AbCellera Biologics slowly grinding toward 2029 earnings of $6.9 million, the lowest analysts paint a much harsher liquidity risk. They were working off revenue projections of just $5.8 million and earnings of $920,000, with a very high implied P/E. Use those bearish pre news assumptions as a foil and examine how fresh data or tools like LensAI and BioNeMo might influence that narrative.

    Explore 4 other AbCellera Biologics fair value estimates, including one that suggests as much as 24% downside from the current price.

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own analysis.

    Looking For More Investment Ideas Beyond AbCellera Biologics?

    If the AbCellera Biologics story has you rethinking how you build exposure to healthcare, it can help to line it up against a few different styles of opportunity using the Simply Wall St Screener.